List view / Grid view
10 to 20 percent of individuals that get COVID-19 will be later diagnosed with long COVID. New research looks at blood plasma protein patterns that can improve patient outcomes.
Researchers from Australia explore how viruses can alter brain cells, and thus the functions of our nervous system, leading to neurological symptoms.
Scientists have discovered that a vaccinated San Diego resident has produced antibodies that are effective against multiple variants of SARS-CoV-2, including Omicron. The research also identified three antibodies that can neutralise the virus, giving new insights into different binding mechanisms with the SARS-CoV-2 spike protein. The findings could help to…
A recent study led by the Lieber Institute for Brain Development has revealed that over 100 genes associated with the risk of schizophrenia appear to contribute to the development of the illness primarily through their influence on the placenta.
As new variants of the SARS-CoV-2 virus emerge, leading scientists Dr Oscar Bastidas and Dr Zoran Sevarac explore how their latest research identified a structured frequency domain profile in data with no discernible pattern. Their article also emphasises that it remains imperative to continue learning about this pathogen’s molecular machinery…
Brad Sorenson, CEO of Providence Therapeutics, shares the future developments and exciting potential of mRNA therapies, including improved efficacy and wider access to vaccines, and future promise for cancer treatment.
The Omicron variant of the SARS CoV-2 virus has previously had a number of break-through infections. However, researchers have discovered that antibodies present in previously infected patients can neutralise variants of the COVID-19 disease.
By creating a drug that is based on part of the SARS-CoV-2 spike protein, US and Finnish researchers can block the virus from entering cells.
In this article Drug Target Review's Izzy Wood highlights three of the latest findings using lab automation techniques and technologies that aid scientists.
The resulting compounds, which can bind to spike proteins from the original coronavirus, could serve as a starting point for developing broad-spectrum treatments for COVID-19.
An AI strategy developed by US scientists could accelerate the development of new antibody drugs.
Researchers have found a potential therapeutic target less vulnerable to potential drug resistance and emerging COVID-19 variants of concern.
Drug discovery trends in 2023 will change the way we conduct science and result in entirely new, more efficient, and effective research paradigms. Through increased public-private partnerships, multidisciplinary collaboration and patient engagement in the drug discovery process, we will see new vaccines and therapies getting to the public faster and…
US researchers find that SARS-CoV-2 bivalent antibodies can continue to neutralise Omicron and Omicron lineages.
US scientists have designed a mathematical model that can predict COVID-19 vaccines’ effectiveness over the long term in healthy individuals and those who have cancer or suppressed immune responses.
